Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lindsay Pattison

Neurology Crestview Hills, KY Doctor of Osteopathy

NPI 1174818009 CMS profile 852078

2670 Chancellor Drive, Crestview Hills, KY 41017

Open in the dashboard

General payments

$2,834

176 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsay Pattison of Crestview Hills, KY is reported in the CMS Open Payments database as having received $2,834 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $578 28
2024 General $604 24
2023 General $324 14
2022 General $253 14
2021 General $246 15
2020 General $235 15
2019 General $594 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsay Pattison
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Lindsay Pattison were reported at $578. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Lindsay Pattison Neurology median Middle half National median
2019 $594 $474 $118–$2,177 $163
2020 $235 $367 $82–$2,309 $114
2021 $246 $438 $104–$2,547 $132
2022 $253 $442 $103–$2,388 $149
2023 $324 $464 $119–$2,312 $160
2024 $604 $468 $119–$2,323 $164
2025 $578 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $372 24 payments
  2. Jazz Pharmaceuticals Inc. $239 12 payments
  3. Amneal Pharmaceuticals LLC $169 11 payments
  4. Supernus Pharmaceuticals, Inc. $165 30 payments
  5. UCB, Inc. $147 7 payments
  6. E.R. Squibb & Sons, L.L.C. $117 1 payment
  7. Lilly USA, LLC $109 7 payments
  8. Amgen Inc. $100 5 payments
  9. AbbVie, Inc. $97 6 payments
  10. Vanda Pharmaceuticals Inc. $93 3 payments
  11. Other $1,225 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,812 175 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21 1 payment
Products named General payments · program years 2019–2025
  1. Epidiolex $244 12 payments
  2. TYSABRI $152 9 payments
  3. OXTELLAR XR $139 24 payments
  4. RYTARY $131 9 payments
  5. TECFIDERA $127 12 payments
  6. AIMOVIG $119 6 payments
  7. VUMERITY $118 6 payments
  8. ZEPOSIA $117 1 payment
  9. PONVORY $93 3 payments
  10. EMGALITY $90 6 payments
  11. Other $1,546 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

663

Median for Neurology: 833

Drug cost

$145,654

Median for Neurology: $202,670

Branded share of claims

34.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Copaxone Glatiramer Acetate Brand 12 $69,984
Glatopa Glatiramer Acetate Brand 12 $32,256
Nurtec Odt Rimegepant Sulfate Brand 14 $22,640
Teriflunomide Generic 14 $6,855
Propranolol Hcl Er Propranolol Hcl Brand 61 $2,755
Carbidopa-Levodopa Carbidopa/Levodopa Brand 101 $2,522
Memantine Hcl Generic 104 $1,841
Levetiracetam Generic 55 $1,759
Memantine Hcl Er Memantine Hcl Brand 26 $1,559
Gabapentin Generic 74 $1,434

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$46,400

Medicare's payments for the services billed

Medicare patients

299

Average age 75

Services billed

578

164 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Chronic kidney disease 45%
Ischemic heart disease 39%
Depression 39%
Diabetes 36%
Atrial fibrillation 30%
Alzheimer's or dementia 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPOSIA
  • E.R. Squibb & Sons, L.L.C. $117
$117 — —
PONVORY
  • Vanda Pharmaceuticals Inc. $93
$93 — —
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $38
$38 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $32
$32 — —
Qutenza
  • Averitas Pharma Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record